CCM
CYT

CAAS Capital Management’s Cyteir Therapeutics, Inc. Common Stock CYT Stock Holding History

CAAS Capital Management’s Portfolio CYT Stock Details CYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-26,175
Closed -$79.6K – 674
2023
Q4 		$79.6K Hold
26,175
– – 0.01% 423
2023
Q3 		$74.3K Sell
26,175
-8,361
-24% -$23K ﹤0.01% 568
2023
Q2 		$89.8K Sell
34,536
-115,870
-77% -$243K 0.01% 594
2023
Q1 		$274K Sell
150,406
-309,373
-67% -$503K 0.01% 499
2022
Q4 		$759K Sell
459,779
-157,043
-25% -$252K 0.05% 316
2022
Q3 		$1.27M Buy
616,822
+536,938
+672% +$1.4M 0.06% 338
2022
Q2 		$239K Sell
79,884
-25,207
-24% -$64.4K 0.01% 643
2022
Q1 		$396K Sell
105,091
-372,419
-78% -$2.12M 0.02% 415
2021
Q4 		$5.43M Sell
477,510
-102,236
-18% -$1.56M 0.13% 173
2021
Q3 		$10.2M Buy
579,746
+79,746
+16% +$1.49M 0.2% 113
2021
Q2 		$10.7M Buy
+500,000
New +$9.37M 0.18% 135

Other funds holding CYT

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BFO
Boston Family Office Boston, Massachusetts $1.5B AUM 11.68% 1-Year Est. Return
LC
Lindbrook Capital Calabasas, California $1.08B AUM 10.14% 1-Year Est. Return

CAAS Capital Management's CYT Position: Q1 2024 in Review

CAAS Capital Management sold out of Cyteir Therapeutics, Inc. Common Stock (CYT) in Q1 2024, closing a stake of 26,175 shares — an estimated $79.6K sold.

CAAS Capital Management first reported a position in CYT in Q2 2021 and held it in 11 quarters. The position peaked at $10.7M in Q2 2021. 4 funds tracked by Wall St. Rank hold CYT as of Q1 2024.

  • CAAS Capital Management reported no remaining Cyteir Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • CAAS Capital Management sold 26,175 Cyteir Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $79.6K.
  • CAAS Capital Management first reported a position in Cyteir Therapeutics, Inc. Common Stock in Q2 2021 and held it in 11 quarters.
  • CAAS Capital Management's Cyteir Therapeutics, Inc. Common Stock position peaked at $10.7M in Q2 2021.
  • 4 funds tracked by Wall St. Rank held Cyteir Therapeutics, Inc. Common Stock as of Q1 2024.

Based on CAAS Capital Management's 13F filing for Q1 2024, filed 26 Apr 2024.